TRT on TikTok: separating real benefits from bro-science

What did @hexumlitee actually say?

Straightforward enough: the creator says it's been two weeks since stopping what sounds like a GLP-1 receptor agonist ("red eye" appears to be slang, likely referring to Ozempic or a similar semaglutide product). Their verdict is blunt. "My hunger signals and the food noise are back in full effect to 100%." They ate steak and rice in the morning and called it a setback. No exaggeration, no dramatic claims, just a personal account of appetite returning quickly after discontinuation.

This is anecdotal, obviously. But anecdote doesn't mean wrong. The creator isn't making any medical claims about the drug itself, just reporting their own subjective experience. That matters for how we evaluate it.

Does the science back this up?

Yes, and pretty clearly. The rapid return of appetite after stopping GLP-1 receptor agonists is one of the most well-documented and underreported aspects of these medications. This isn't a surprise finding buried in a footnote.

Wilding et al. (2022, The New England Journal of Medicine) published the STEP 1 trial extension showing that participants who stopped semaglutide regained roughly two-thirds of their lost weight within one year. The mechanism isn't mysterious: GLP-1 receptor agonists work in part by suppressing appetite signaling in the hypothalamus and slowing gastric emptying. When the drug clears your system, those effects go with it.

The half-life of semaglutide (as in Ozempic or Wegovy) is approximately one week. That means by week two, plasma concentrations have dropped substantially. The pharmacokinetics line up almost perfectly with what the creator describes. "Food noise" returning at two weeks post-dose is biologically consistent, not a fluke.

What did they get wrong (or right)?

Honestly, they got the core observation right. The timeline is plausible, the symptom description is accurate, and they're not overselling anything. Credit where it's due.

What's missing, though, is context that matters. Saying hunger is "back to 100%" implies a binary: drug on, hunger off; drug off, hunger on. The reality is more graduated. Blundell et al. (2017, Diabetes, Obesity and Metabolism) showed that GLP-1 receptor agonists modulate multiple appetite pathways, and individual variation in how quickly those pathways rebound is significant. Some people report a slower return of appetite; others report it faster.

The creator also doesn't address why they stopped, which is clinically relevant. Stopping a GLP-1 agonist intentionally versus running out versus side effects produces different contexts for interpreting what comes next. That gap doesn't make them wrong, but it limits how much viewers should generalize from this single experience.

What should you actually know?

If you're on a GLP-1 receptor agonist and considering stopping, the evidence suggests appetite suppression does not persist after the drug clears. That's not a personal failure; that's pharmacology.

Rubino et al. (2021, JAMA) found that weight regain after semaglutide discontinuation was nearly universal without sustained lifestyle intervention. The drug is managing a physiological process, not resetting it permanently. This is why most clinical guidelines treat GLP-1 agonists as chronic medications for obesity, not short-term fixes.

"Food noise" is also a real phenomenon with a neurobiological basis, not just willpower language. Research using fMRI (Batterham et al., 2007, Cell Metabolism) has shown GLP-1 receptor activity in brain regions tied to food reward and attention. When that activity drops, cognitive preoccupation with food can return sharply. The creator's description is consistent with that mechanism.

If you're managing your weight or hormonal health through a telehealth platform, talk to your provider before stopping any medication. Two weeks of personal data is interesting, but it's one data point.